Cellectar Biosciences, Inc.
CLRB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLRB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLRB
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing cancer treatments using its proprietary phospholipid ether drug conjugate (PDC) delivery platform.
Key risk: Going concern uncertainty
BioSniper Score
Based on 6 of 6 signals
Market Cap
$23.9M
Cash Runway
17.1 moLead Asset
CLR 121125 (Phase 1)
Next Catalyst
Phase3_Topline · Jan 1, 2035Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials · 1 catalyst for Cellectar Biosciences, Inc..
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing cancer treatments using its proprietary phospholipid ether drug conjugate (PDC) delivery platform.
- Cellectar is a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer [sec_mda · as of 2026-03-04].
- The company's core objective is to leverage its proprietary phospholipid ether drug conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells [sec_mda · as of 2026-03-04].
- As of 2026-06-30, the company reported cash & equivalents of $34.0M, a net loss of -$6.9M, and shareholders' equity of $8.5M [sec].
- The company plans to submit a New Drug Application (NDA) to the FDA for accelerated approval of iopofosine I 131 for Waldenström macroglobulinemia (WM), subject to sufficient funding [sec_mda · as of 2026-03-04].
- There is substantial doubt about the company's ability to continue as a going concern within one year, dependent on raising sufficient capital or obtaining partners [sec · filed 2026-05-19].
What works
- The company's proprietary PDC platform is designed to specifically target cancer cells, potentially offering improved efficacy and better safety due to fewer off-target effects [sec_mda · as of 2026-03-04].
- Cellectar has multiple ongoing clinical programs, including a Phase 3 trial for iopofosine I 131 in Waldenström macroglobulinemia and a Phase 1b study in pediatric high-grade glioma [sec_mda · as of 2026-03-04].
- The company plans to submit an NDA for accelerated approval of iopofosine I 131 for WM, indicating progress toward regulatory milestones [sec_mda · as of 2026-03-04].
What to weigh
- The company has a going concern uncertainty, as its ability to continue depends on raising sufficient capital or securing partners [sec · filed 2026-05-19].
- Cellectar reported a net loss of -$6.9M for the period ending 2026-06-30, reflecting ongoing operational cash burn [sec].
- Even if successfully developed, there is no guarantee of market acceptance for the company's products, and competitors may develop superior or less costly alternatives [sec · filed 2026-05-19].
From the filings
Quoted directly from source documents.
Cellectar is a late-stage clinical biopharmaceutical company focused on cancer drug development using its PDC platform.
“We are a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer.”
SEC MD&A · March 4, 2026
The company has a going concern uncertainty.
“the necessary funding, raising substantial doubt about the Company's ability to continue as a going concern within one year of the date these financial statements are issued.”
SEC filings · May 19, 2026
The company plans to submit an NDA for accelerated approval of iopofosine I 131 for WM.
“The Company plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the accelerated approval of iopofosine I 131 as a treatment for WM once the confirmatory trial is underway, which is subject to sufficient funding.”
SEC MD&A · March 4, 2026
The company's PDC platform is designed to specifically target cancer cells.
“Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.”
SEC MD&A · March 4, 2026
Catalyst timeline
- 2035-01-01 · Phase3_Topline · iopofosine — Phase 3 Topline: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophos — Topline results from the Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia are expected, which will be a key data readout for the program.
Risks & what to watch (3)›
Key risks
- Going concern uncertainty — Substantial doubt about ability to continue as a going concern within one year, dependent on raising capital or securing partners [sec · filed 2026-05-19].
- Dependence on funding for NDA — Planned NDA submission for iopofosine I 131 is subject to sufficient funding, which is not assured [sec_mda · as of 2026-03-04].
- Market acceptance risk — No guarantee of market acceptance even if products are developed and approved; competitors may offer superior alternatives [sec · filed 2026-05-19].
What to watch
- Phase 3 topline data for iopofosine I 131 in Waldenström macroglobulinemia, expected by 2035-01-01 [catalyst].
- Company's ability to secure sufficient funding to continue operations and submit the NDA for iopofosine I 131 [sec_mda · as of 2026-03-04].
- Enrollment progress in the Phase 1b study for pediatric high-grade glioma [sec_mda · as of 2026-03-04].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Cellectar Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cellectar Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
17.1 months
D/E 0.23 · 0% dilution
Lead: Phase 1
2 candidates
1 upcoming, next in ~3046d
2 buys · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$607K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 163,768 | $416K |
| geode capital management, llc | 52,778 | $134K |
| vanguard fiduciary trust co | 16,573 | $42K |
| blackrock, inc. | 4,745 | $12K |
| vanguard global advisers, llc | 563 | $1K |
| morgan stanley | 510 | $1K |
| td waterhouse canada inc. | 63 | $154 |
| sbi securities co., ltd. | 11 | $28 |
| fmr llc | 10 | $25 |
| jones financial companies lllp | 3 | $8 |
Showing top 10 of 13 institutional holders of Cellectar Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.5%
- Days to cover
- 0.8
- Shares short
- 22,951
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLRB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cellectar Biosciences, Inc.?
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing cancer treatments using its proprietary phospholipid ether drug conjugate (PDC) delivery platform.
What is Cellectar Biosciences, Inc.'s lead drug candidate?
Cellectar Biosciences, Inc.'s most advanced tracked candidate is CLR 121125 (Phase 1) for Triple negative breast cancer (TNBC).
What is Cellectar Biosciences, Inc.'s next catalyst?
Cellectar Biosciences, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophos" — expected January 1, 2035.
Who is the CEO of Cellectar Biosciences, Inc.?
Mr. James V. Caruso is the chief executive officer of Cellectar Biosciences, Inc. (CLRB).
Where is Cellectar Biosciences, Inc. headquartered?
Cellectar Biosciences, Inc. (CLRB) is headquartered in Florham Park, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.